Group 1 - Pomerantz LLP is investigating claims on behalf of investors of NuScale Power Corporation regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - Citigroup downgraded NuScale from Neutral/High Risk to Sell/High Risk on October 21, 2025, citing competition from new entrants and the lack of a binding customer contract [2] - Following the downgrade, NuScale's stock price fell by $9.49 per share, or 21.47%, closing at $34.72 per share on October 22, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Alector, Inc. following disappointing clinical trial results for its drug, latozinemab, which did not meet primary endpoints [1][2]. Group 1: Company Overview - Alector, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases [2]. - The company recently announced results from the Phase 3 INFRONT-3 clinical trial for latozinemab, which targets frontotemporal dementia due to a progranulin gene mutation [2]. Group 2: Clinical Trial Results - The Phase 3 clinical trial results indicated that latozinemab failed to meet its clinical co-primary endpoint of slowing the progression of frontotemporal dementia [2]. - Secondary and exploratory endpoints, including fluid biomarkers and volumetric magnetic resonance imaging (vMRI), showed no treatment-related effects [2]. Group 3: Market Reaction - Following the announcement of the trial results, Alector's stock price dropped by $1.60 per share, representing a decline of 49.84%, closing at $1.61 per share on October 22, 2025 [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Semler Scientific, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose a material investigation by the U.S. Department of Justice [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 10, 2021, to April 15, 2025 [2]. - Allegations include that Semler Scientific did not disclose a material investigation by the U.S. Department of Justice related to violations of the False Claims Act [2]. - The deadline for shareholders to register for the class action is October 28, 2025 [3]. Group 2: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for allegedly making false and misleading statements regarding a material investigation by the U.S. Department of Justice related to the False Claims Act, which has resulted in investor losses [3][7]. Allegation Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the DOJ into potential violations of the False Claims Act while discussing such violations in hypothetical terms [3]. - As a result of these omissions, the public statements made by the defendants were materially false and misleading throughout the relevant period [3]. Next Steps for Investors - Investors who purchased Semler shares between March 10, 2021, and April 15, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28th [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance, leading to investor losses during the specified Class Period [3][7]. Allegation Details - The lawsuit claims that LifeMD's defendants overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [3]. - It is alleged that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 27, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with the U.S. Department of Defense's Transportation Command, leading to investor losses during the specified class period [3][7]. Allegation Details - The complaint alleges that KBR was aware of concerns from TRANSCOM about HomeSafe's ability to fulfill its Global Household Goods Contract for several months but failed to disclose this information [3]. - KBR allegedly misled investors by claiming that its partnership with TRANSCOM would continue to grow despite these concerns [3]. - The company's public statements during the class period are claimed to be false and materially misleading, resulting in damages to investors when the truth was revealed [3]. Next Steps - Investors who purchased KBR shares between May 6, 2025, and June 19, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Points - A class action lawsuit has been filed against RCI Hospitality Holdings, Inc. (NASDAQ: RICK) for allegedly making materially false and misleading statements regarding tax fraud and bribery [7] - The lawsuit claims that the defendants understated the legal risks facing the company, leading to investor damages when the true details were revealed [3] Allegation Details - Defendants allegedly engaged in tax fraud and bribery to conceal this fraud [3] - The lawsuit asserts that the defendants' statements about the company's business, operations, and prospects were materially false and lacked a reasonable basis [3] Next Steps - Investors who purchased RCI shares between December 15, 2021, and September 16, 2025, and suffered losses are encouraged to contact the law firm for more information [4][7] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 20, 2025 [7]

Core Viewpoint - A class action lawsuit has been filed against Quanex Building Products Corporation for allegedly making materially false and misleading statements regarding its business operations and prospects during the specified class period [3][7]. Allegation Details - The lawsuit claims that Quanex failed to disclose significant underinvestment in tooling and equipment maintenance at its Tyman Mexico facility, leading to degraded conditions [3]. - It is alleged that the company was likely to incur substantial costs due to these issues, which would delay the expected benefits from the Tyman integration [3]. - The complaint asserts that Quanex had previously identified these problems but did not disclose them, rendering its positive statements about the company's operations misleading [3]. Next Steps - Investors who purchased Quanex shares between December 12, 2024, and September 5, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that during the class period from March 7, 2024, to May 23, 2025, Savara did not disclose that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely [8]. - The complaint also states that the delay in regulatory approval would likely necessitate Savara to raise additional capital [8]. - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [8]. Next Steps - Investors who purchased Savara shares and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the specified class period from January 30, 2025, to July 23, 2025 [1][7]. Allegation Details - Defendants are accused of overstating Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, declining global sales, and product oversupply on Dow's business were allegedly understated [3]. - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Dow shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].